Found: 37
Select item for more details and to access through your institution.
Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 10, p. 7565, doi. 10.1007/s00432-023-04678-2
- By:
- Publication type:
- Article
Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 9, p. 5591, doi. 10.1007/s00432-022-04512-1
- By:
- Publication type:
- Article
Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2021, v. 147, n. 12, p. 3665, doi. 10.1007/s00432-021-03602-w
- By:
- Publication type:
- Article
The Prognostic Role of Early Skeletal Muscle Mass Depletion in Multimodality Management of Patients with Advanced Gastric Cancer Treated with First Line Chemotherapy: A Pilot Experience from Modena Cancer Center.
- Published in:
- Journal of Clinical Medicine, 2021, v. 10, n. 8, p. 1705, doi. 10.3390/jcm10081705
- By:
- Publication type:
- Article
Could Inflammatory Indices and Metabolic Syndrome Predict the Risk of Cancer Development? Analysis from the Bagnacavallo Population Study.
- Published in:
- Journal of Clinical Medicine, 2020, v. 9, n. 4, p. 1177, doi. 10.3390/jcm9041177
- By:
- Publication type:
- Article
Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma.
- Published in:
- Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-22543-z
- By:
- Publication type:
- Article
Exceptional response to lurbinectedin and irinotecan in BRCA -mutated platinum-resistant ovarian cancer patient: a case report.
- Published in:
- Therapeutic Advances in Chronic Disease, 2022, p. 1, doi. 10.1177/20406223211063023
- By:
- Publication type:
- Article
Exceptional response to lurbinectedin and irinotecan in BRCA-mutated platinumresistant ovarian cancer patient: a case report.
- Published in:
- Therapeutic Advances in Chronic Disease, 2022, p. 1, doi. 10.1177/20406223211063023
- By:
- Publication type:
- Article
Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experience.
- Published in:
- Therapeutic Advances in Medical Oncology, 2023, p. 1, doi. 10.1177/17588359231171574
- By:
- Publication type:
- Article
The beneficial impact of metabolic dysfunction‐associated fatty liver disease on lenvatinib treatment in patients with non‐viral hepatocellular carcinoma.
- Published in:
- Hepatology Research, 2023, v. 53, n. 2, p. 104, doi. 10.1111/hepr.13843
- By:
- Publication type:
- Article
Validation of the easy‐to‐use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib.
- Published in:
- Hepatology Research, 2022, v. 52, n. 12, p. 1050, doi. 10.1111/hepr.13824
- By:
- Publication type:
- Article
Lenvatinib versus Sorafenib as first‐line treatment in hepatocellular carcinoma: A multi‐institutional matched case‐control study.
- Published in:
- Hepatology Research, 2021, v. 51, n. 12, p. 1229, doi. 10.1111/hepr.13718
- By:
- Publication type:
- Article
Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with regorafenib.
- Published in:
- Hepatology Research, 2021, v. 51, n. 7, p. 796, doi. 10.1111/hepr.13669
- By:
- Publication type:
- Article
The Prognostic Value of the New Combined Hemo-Eosinophil Inflammation Index (HEI Index): A Multicenter Analysis of Anal Cancer Patients Treated with Concurrent Chemo-Radiation.
- Published in:
- Cancers, 2021, v. 13, n. 4, p. 671, doi. 10.3390/cancers13040671
- By:
- Publication type:
- Article
Impact of body mass index on the prognosis of unresectable HCC patients receiving first‐line Lenvatinib or atezolizumab plus bevacizumab.
- Published in:
- Liver International, 2024, v. 44, n. 5, p. 1108, doi. 10.1111/liv.15885
- By:
- Publication type:
- Article
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data.
- Published in:
- Liver International, 2023, v. 43, n. 8, p. 1803, doi. 10.1111/liv.15641
- By:
- Publication type:
- Article
Incidence and Predictors of Esophagogastric Varices Bleeding in Patients with Hepatocellular Carcinoma in Lenvatinib.
- Published in:
- Liver Cancer (2235-1795), 2024, v. 13, n. 2, p. 215, doi. 10.1159/000534127
- By:
- Publication type:
- Article
Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 6, p. 527, doi. 10.1159/000525145
- By:
- Publication type:
- Article
Platinum sensitivity in patients with IDH1/2 mutated vs wild‐type intrahepatic cholangiocarcinoma: A propensity score‐based study.
- Published in:
- International Journal of Cancer, 2022, v. 151, n. 8, p. 1310, doi. 10.1002/ijc.34182
- By:
- Publication type:
- Article
Combined Loco-Regional and Systemic Treatment Strategies for Hepatocellular Carcinoma: From Basics to New Developments.
- Published in:
- CardioVascular & Interventional Radiology, 2023, v. 46, n. 2, p. 175, doi. 10.1007/s00270-022-03327-4
- By:
- Publication type:
- Article
Genomic profiling of small bowel adenocarcinoma: a pooled analysis from 3 databases.
- Published in:
- British Journal of Cancer, 2024, v. 131, n. 1, p. 49, doi. 10.1038/s41416-024-02687-7
- By:
- Publication type:
- Article
Irinotecan-based chemotherapy in extrapulmonary neuroendocrine carcinomas: survival and safety data from a multicentric Italian experience.
- Published in:
- Endocrine (1355008X), 2021, v. 74, n. 3, p. 707, doi. 10.1007/s12020-021-02813-y
- By:
- Publication type:
- Article
A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy.
- Published in:
- Acta Oncologica, 2021, v. 60, n. 10, p. 1317, doi. 10.1080/0284186X.2021.1953704
- By:
- Publication type:
- Article
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy.
- Published in:
- Cancer Management & Research, 2021, v. 13, p. 9379, doi. 10.2147/CMAR.S330195
- By:
- Publication type:
- Article
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study.
- Published in:
- Targeted Oncology, 2024, v. 19, n. 3, p. 359, doi. 10.1007/s11523-024-01060-1
- By:
- Publication type:
- Article
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab.
- Published in:
- Targeted Oncology, 2024, v. 19, n. 4, p. 645, doi. 10.1007/s11523-024-01061-0
- By:
- Publication type:
- Article
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab.
- Published in:
- Targeted Oncology, 2024, v. 19, n. 2, p. 223, doi. 10.1007/s11523-024-01032-5
- By:
- Publication type:
- Article
Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma.
- Published in:
- Targeted Oncology, 2024, v. 19, n. 1, p. 29, doi. 10.1007/s11523-023-01029-6
- By:
- Publication type:
- Article
Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?
- Published in:
- Targeted Oncology, 2023, v. 18, n. 2, p. 221, doi. 10.1007/s11523-023-00953-x
- By:
- Publication type:
- Article
Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients.
- Published in:
- Targeted Oncology, 2023, v. 18, n. 1, p. 139, doi. 10.1007/s11523-022-00933-7
- By:
- Publication type:
- Article
Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience.
- Published in:
- Targeted Oncology, 2021, v. 16, n. 5, p. 653, doi. 10.1007/s11523-021-00834-1
- By:
- Publication type:
- Article
Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Correction to: Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis.
- Published in:
- 2021
- By:
- Publication type:
- corrected article
Effects of Metformin and Vitamin D on Clinical Outcome in Cholangiocarcinoma Patients.
- Published in:
- Oncology, 2021, v. 99, n. 5, p. 292, doi. 10.1159/000512796
- By:
- Publication type:
- Article
Validation and refinement of PROSASH model using the neutrophil-to-lymphocyte ratio in patients with HCC receiving sorafenib.
- Published in:
- Liver Cancer International, 2020, v. 1, n. 1, p. 6, doi. 10.1002/lci2.12
- By:
- Publication type:
- Article
Clinical Implications of Malnutrition in the Management of Patients with Pancreatic Cancer: Introducing the Concept of the Nutritional Oncology Board.
- Published in:
- Nutrients, 2021, v. 13, n. 10, p. 3522, doi. 10.3390/nu13103522
- By:
- Publication type:
- Article